empagliflozin
eli lilly,boehringer ingelheim
['empag', 'empagliflozin', 'cardio', 'empa-kidney']
today at #aha22 'empagliflozin and #cardiovascular outcomes in patients with chronic kidney disease: the empa-kidney trial' presented by dr david preiss 6 november 5.26pm cst
room: main event i 
Nuffield Department of Population Health | @UniofOxford | Tweets about health, our research and impact | #RECOVERYTrial